XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

Scor investors’ bad year can still get worse



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-Scor investors’ bad year can still get worse</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

By Aimee Donnellan

LONDON, July 16 (Reuters Breakingviews) -Scor SCOR.PA investors must be wishing they had access to a time machine. It’s six years since the 3.5 billion euro French reinsurer fought off a hostile takeover from its domestic rival Covéa, which valued the company at 43 euros per share. In 2024 problems in its life and health unit, revealed on Tuesday, mean it’s now worth less than half that. And there could be further strife to come.

Covéa and Scor’s arm wrestle began in 2018 when Scor rejected a takeover from the French mutual insurer. In 2019 lawsuits alleged that while Covéa CEO Thierry Derez was sitting on Scor’s board, he used confidential information to advance his own bid. Covéa denied wrongdoing but said the “continued attacks and hostile tactics” made it drop its plans. Eventually, in 2021, Covéa agreed to sell its stake in Scor and vowed not to buy any of its former target’s shares for seven years.

That pact now looks unfortunate, given Scor’s headaches. On Tuesday, the company’s shares collapsed 26% to just 19 euros a share after CEO Thierry Léger flagged that it may have to book a 500 million euro net loss in the health unit. More worryingly, Scor said the dent to its life and health business will impact the company’s solvency which will now merely be above 200% of regulatory minimum requirements, compared to 209% at the end of last year.

Investors should have two concerns. One is that the life insurance goof – partly down to mistaken assumptions that slow Covid-era claims rates would persist – could have been avoided. The other is that Scor’s property and casualty division, which pays out claims on damage from hurricanes and other natural disasters and accounts for around half of Scor’s 19.4 billion euros of premiums, may also drain capital. After all, the tropical storm season is just beginning and could lead to big payouts. The risk is Scor’s solvency sinks below the foot of its targeted 185% to 220% range.

If so, Scor might have to raise equity to bolster its reserves. That sort of uncertainty means potential suitors like domestic giant Axa AXAF.PA or private equity firms may not fancy lobbing in an opportunistic bid to take advantage of the company’s share implosion – and Covéa can’t. How Scor investors must pine for 2018.

Follow @aimeedonnellan on X


CONTEXT NEWS

Shares in Scor fell 26% on July 16 after the French reinsurer cut guidance for its life and health (L&H) unit.

The unit’s second-quarter insurance service result (ISR), a measure of profitability, is expected to fall to a loss of about 400 million euros and the full-year ISR is expected to be significantly less than the 500 million euros guided before, Scor says.

As of 0956 GMT, Scor shares were trading at 19.8 euros, down 24%.


Graphic: Scor’s share price has fallen far below Covéa’s 2018 offer https://reut.rs/3Y08eNl


Editing by George Hay and Oliver Taslic

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.